Search Results

You are looking at 91 - 100 of 1,474 items for :

  • metabolic disease x
  • Refine by Access: All content x
Clear All
Free access

Steve O'Rahilly

Wellcome Trust and the NIHR Cambridge Biomedical research centre for continuing support of research in the area of obesity and related metabolic disease. Reference Ahima RS Prabakaran D Mantzoros C Qu D Lowell B Maratos-Flier E Flier JS 1996

Open access

Esther Nuñez-Durán, Belén Chanclón, Silva Sütt, Joana Real, Hanns-Ulrich Marschall, Ingrid Wernstedt Asterholm, Emmelie Cansby, and Margit Mahlapuu

Introduction Type 2 diabetes, characterised by hyperglycaemia in the context of insulin resistance, is one of the most common metabolic diseases in the world. Insulin production from pancreatic β-cells plays a vital role in maintaining the

Free access

Patricia Cristine Borck, Sarah Rickli, Jean Franciesco Vettorazzi, Thiago Martins Batista, Antonio Carlos Boschero, Elaine Vieira, and Everardo Magalhães Carneiro

obesity, T2D and cardiovascular diseases. Recent evidence indicates that exposure to artificial light at night (ALAN) disrupts the circadian rhythms and leads to the development of metabolic disorders ( Boivin & Boudreau 2014 , Dibner & Schibler 2015

Free access

J D Bailey, J G Berardinelli, T E Rocke, and R A Bessen

SB 1998 Prions . PNAS 95 13363 – 13383 . Rowland N 1984 Metabolic fuel homeostasis in golden hamsters: effects of fasting, refeeding, glucose, and insulin . American Journal of Physiology 247 R57 – R62 . Salman MD 2003 Chronic wasting disease in

Free access

Leke Wiering and Frank Tacke

other diseases of the metabolic syndrome and is partly described as its hepatic manifestation. Thus, in the early stages, cardiovascular events represent the main cause of death in NAFLD, whereas in the later stages, liver-associated causes of death as

Free access

Galya Vassileva, Weiwen Hu, Lizbeth Hoos, Glen Tetzloff, Shijun Yang, Li Liu, Ling Kang, Harry R Davis, Joseph A Hedrick, Hong Lan, Timothy Kowalski, and Eric L Gustafson

the deletion of GPBAR1 has differential effect in males and females. Recently, GPBAR1 has emerged as a promising new target in metabolic disease. Although the relevance of our data to human GPBAR1 biology is not yet established, our findings of a

Open access

Yanli Miao, Haojie Qin, Yi Zhong, Kai Huang, and Caijun Rao

asprosin mainly focused on glucose homeostasis ( Li et al. 2019 ), it has been reported that asprosin is related to a range of metabolic diseases such as non-alcoholic fatty liver disease ( Ke et al. 2020 ), insulin resistance ( Yuan et al. 2020

Free access

Salla Nuutinen, Liisa Ailanen, Eriika Savontaus, and Petteri Rinne

Introduction The most acute complications of cardiovascular diseases originate from atherosclerosis, a chronic inflammatory disease of the middle- and large-sized arteries. One important risk factor for atherosclerosis is the metabolic

Free access

Elisabetta De Marinis, Chiara Martini, Anna Trentalance, and Valentina Pallottini

Introduction Recent research, over the past decade, has been dedicated to the study of the relevant physiologic differences between the sexes that may affect the prevention, diagnosis, and treatment of disease. Dissimilar exposures, susceptibilities

Free access

Li Zhao, Chunfang Zhu, Meng Lu, Chi Chen, Xiaomin Nie, Buatikamu Abudukerimu, Kun Zhang, Zhiyuan Ning, Yi Chen, Jing Cheng, Fangzhen Xia, Ningjian Wang, Michael D Jensen, and Yingli Lu

Introduction Type 2 diabetes mellitus (T2DM) is a complex metabolic disorder that is often associated with obesity, dyslipidemia, hypertension, microvascular disease and other complications ( American Diabetes Association 2016 ). All these